inhsu 2016 conference handbook

5th International Symposium on Hepatitis Care in Substance Users

Wednesday 7 September - Friday 9 September 2016 • Oslo, Norway

INHSU 2016Conference Handbook

@INHepSU • #INHSU16 • inhsu2016.com

Published in 2016 by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine

National Office: Locked Mail Bag 5057 Darlinghurst NSW 1300, Australia

T +61 2 8204 0770 F +61 2 8204 0779 E [email protected] W www.ashm.org.au

ABN: 48 264 545 457 CFN: 17788

© ASHM 2016 Design and layout by Steph Yamey

Printed by Just Cruzin' Production

INHSU 2016 - Conference Handbook 1

CONTENTS

CONFERENCE ENVIRONMENT POLICY

ASHM Conference and Events Division implements a waste-reduction policy that addresses:

� Reduce, Reuse, Recycle. This is done before, during and after each conference.

� ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.

� ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.

� ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.

� ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.

� ASHM Conference & Events Division will endeavour to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.

ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

Poster Listings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Venue Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Location Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Social Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Industry Sponsored Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Exhibition Booth Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

2

WELCOME

Welcome to Oslo!

Dear delegate at INHSU 2016

We want to welcome you to Oslo and the 5th International Symposium on Hepatitis Care in Substance Users 7 - 9 September, 2016. We have a very exciting programme for you.

Hepatitis C is a main health problem among people who inject drugs. We do have effective drugs against hep C available today, but only a small minority of those who use drugs actually have access to them. This has to change! We therefore think the conference should discuss the following issues: 1) HCV epidemiology, screening, assessment; 2) HCV treatment and care; and 3) HCV treatment access and implementation. A new feature of this year’s conference is the workshops which will bring together health professionals, researchers, community organisations, people who use drugs and policy makers. We hope this will facilitate change in the field of hepatitis C in people who use drugs.

INHSU 2016 is organized by the International Network on Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. INHSU 2016 is sponsored by AbbVie, Bristol Myers Squibb, Gilead, Janssen, MSD, Open Society Foundations, Akershus University Hospital and The Norwegian Research Fund.

We hope that you enjoy the conference as well as the pleasures that Oslo and its surrounding areas have to offer.

Regards,

Professor Olav Dalgard, Akershus University Hospital Conference Chair


The 2016 INHSU Committee would like to thank all the sponsors, supporters, presenters and participants who helped bring this Conference together.

On behalf of the Organising Committee:

OLAV DALGARD Akershus University Hospital, Norway

HÅVARD MIDGARD Akershus University Hospital, Norway

JASON GREBELY The Kirby Institute, UNSW, Australia

Local Scandinavian Committee:

KJERSTI ULSTEIN HCV Clinic, Oslo, Norway

ØYSTEIN BACKE HCV Clinic, Oslo, Norway

KRISTIN VENNESLAND HCV Clinic, Oslo, Norway

KNUT BOE KIELLAND Innlandet Hospital Trust, Norway

RONNY BJØRNESTAD ProLAR, Norway

BENT ARILD STORNES ProLAR, Norway

PEER BREHM CHRISTENSEN University of Southern Denmark, Denmark

ANNE ØVREHUS University of Southern Denmark, Denmark

MARTIN KÅBERG Karolinska Institutet, Sweden

AMY SARGENT Project Officer, ASHM Conference & Events Division, Australia

NADINE GIATRAS Division Manager, ASHM Conference & Events Division, Australia

4

GENERAL INFORMATION

CONFERENCE VENUE

Holbergsgate 300166 Oslo, NorwayTel: +47 23 29 30 00 • Fax: +47 23 29 30 01Email: [email protected]

REGISTRATION DESK

Foyer, Radisson Blu Scandinavia Hotel

The INHSU conference registration will be open from 8.00am, Wednesday 7 September 2016.

NAME BADGES

For security purposes all attendees must wear their name badge at all times whilst in the Radisson Blu Scandinavia Hotel. If you misplace your name badge, please advise staff at the Registration Desk.

INTERNET AREA

An Internet area is available for the duration of the meeting in the Foyer, Radisson Blu Scandinavia Hotel.

The internet hub and wireless internet access for the INHSU Conference has been proudly sponsored by MSD.

CATERING

Morning and afternoon tea breaks will be served in the Exhibition Area in the Foyer. Lunch will be served in Holberg Restaurant. The conference catering has been proudly sponsored by Abbvie

JUICE BAR

A Juice Bar will be available to delegates during morning and afternoon tea breaks and served in the Exhibition area. The Juice Bar has been proudly sponsored by Janssen.

SPEAKER PREPARATION DESK

The speaker preparation room will be located in the Asker room.

All speakers must take their presentation to the speaker preparation desk a minimum of four hours prior to their presentation or the day before if presenting at a morning session.

MOBILE PHONES/BEEPERS

As a courtesy to all delegates and speakers, please switch off, or set to silent, your mobile phones and beepers during all sessions.

PERSONAL MAILThe conference organisers do not accept responsibility for personal mail. Please have all mail sent to your accommodation address.

SMOKING This conference has a no smoking policy.

POSTER DISPLAYS

Posters will be displayed for the duration of the conference, these are located in the Helsingfors room.

WI-FI INTERNET Username: INHSU • Password: INHSU2016

PARKINGCar parking is available in the hotel garage for an extra charge. All parking is subject to availability.


PROGRAMME: Wednesday 7 September

EPIDEMIOLOGY AND PUBLIC HEALTH

8.00am Registration: Foyer

9.00am - 9.15am

Opening Ceremony

Room: Scandinavia Ballroom

9.00am - 9.10am

Welcome to the Conference Olav Dalgard, Akershus University Hospital, Norway

9.10am - 9.15am

Opening from Community Member Ronny Bjørnestad, proLAR, Norway

9.15am - 10.40am

Session A: HCV Epidemiology

Room: Scandinavia BallroomChairs: Tom Hemming Karlsen, University of Oslo and Magdalena Harris, London School of Hygeine and Tropical Medicine, United Kingdom

9.15am - 9.35am

The Burden of HCV Infection among PWID Sharon Hutchinson, Glasgow Caledonian University, United Kingdom

9.35am - 9.55am

The Natural History of HCV Infection Knut Boe Kielland, Innlandet Hospital Trust, Norway

9.55am - 10.10am

Can Health Risk Behaviours Explain the High Mortality Rate for Adults with Chronic Hepatitis C in the United States? Hamish Innes, Glasgow Caledonian University, United Kingdom

10.10am - 10.25am

Effect of Combined Harm Reduction Strategies on HCV Primary and Reinfection Incidences among People Who Inject Drugs in Montreal, CanadaJulie Bruneau, Université de Montréal, Canada

10.25am - 10.40am

The Prison Economy of Needles and Syringes: What Opportunities Exist for Hepatitis C Risk Reduction When Prices are so High?Carla Treloar, Centre for Social Research in Health, University of New South Wales, Australia

10.40am - 11.00am

Coffee Break in Foyer

11.00am - 12.00pm

Session B: Harm Reduction

Room: Scandinavia BallroomChairs: Matt Hickman, University of Bristol, United Kingdom and Ronny Bjørnestad, proLAR, Norway

11.00am - 11.20am

State-of-the-Art Lecture: Opioid and Stimulant Substitution TreatmentJohan Franck, Karolinska Institutet, Sweden

11.20am - 11.40am

Sharing of Needles, Syringes and Injecting Equipment: Risk of HCV Transmission and Prevention Potential Holly Hagan, New York University, United States of America

11.40am - 12.00pm

Advances and Opportunities for Harm Reduction in Europe Mags Maher, EuroNPUD, United Kingdom

GENERAL INFORMATION

6


12.00pm - 1.45pm

Lunch in Restaurant

12.15pm - 1.15pm

Industry Sponsored Symposium: A Practical Approach to Treating HCV in PWID Room: Stockholm/Oslo

1.45pm - 3.00pm

Session C: Oral Abstracts Epidemiology and Public Health

1.45pm - 3.00pm

Session D: Oral Abstracts Epidemiology and Public Health

Room: København Chairs: Peter Vickerman, University of Bristol, United Kingdom and Angella Duvnjak, Australian Injecting & Illicit Drug Users League, Australia

Room: Stockholm/OsloChairs: Lisa Maher, The Kirby Institute, University of New South Wales, Australia and Chloé Forette, Médecins du Monde, France

1.45pm - 2.00pm

Hepatitis C and HIV Treatment Cascades among People Who Inject Drugs. Results from a Sero-Behavioural Survey among Current Injectors in GermanyRuth Zimmermann, Robert Koch Institute, Germany

1.45pm - 2.00pm

Molecular Epidemiology of Full-Length Hepatitis C Virus Genomes among Injecting Drug Users with Recent Infection: The Inc3 StudyChaturaka Rodrigo, University of New South Wales, Australia

2.00pm - 2.15pm

The Role of Incarceration in HCV Transmission amongst People who Inject Drugs: A Modelling AnalysisJack Stone, University of Bristol, United Kingdom

2.00pm - 2.15pm

Liver Disease Burden and Clinical Follow-Up during a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The Liverlife StudyJason Grebely, Kirby Institute, University of New South Wales, Australia

2.15pm - 2.30pm

Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting: The HITS-P StudyEvan Cunningham, University of New South Wales, Australia

2.15pm - 2.30pm

Successful Model of Testing and Linking People who Inject Drugs (PWID) to Treatment using Direct Acting Antivirals Nalinikanta Rajkumar, Community Network for Empowerment (CoNE), India

2.30pm - 2.45pm

Network-Based Modeling for HCV in US Drug Injectors: Treatment as PreventionAlexei Zelenev, Yale School of Medicine, United States of America

2.30pm - 2.45pm

Changes in Risk Behaviours during and Following Treatment for Hepatitis C Virus Infection among People Who Inject Drugs: The ACTIVATE StudyHåvard Midgard, Akershus University Hospital, Norway

PROGRAMME: Wednesday 7 September



2.45pm - 2.50pm

Monitoring HCV among People Who Inject Drugs in Europe: A Set of Indicators to Serve Policy and PracticeIsabelle Giraudon, European Monitoring Centre for Drugs and Drug Addiction, Portugal

2.45pm - 2.50pm

Exposure to opioid substitution therapy following hepatitis C notification: Implications for provision of antiviral therapies in drug treatment settingsSarah Larney, National Drug and Alcohol Research Centre, University of New South Wales, Australia

2.50pm - 2.55pm

Combining the Expansion of Medicated Assisted Therapies and HCV Treatment among PWID in Ukraine: Insights from Network ModelingAlexei Zelenev, Yale School of Medicine, United States of America

2.50pm - 2.55pm

Fatigue in Patients with Chronic Hepatitis C: The FAT-HEP Study. A Cross Sectional Study of Fatigue and its Relation to Substance Use and OSTsAnne Øvrehus, MD, University of Southern Denmark, Denmark

2.55pm - 3.00pm

HCV Infection and HIV-HCV Coinfection among “New” Injectors during an HIV Outbreak in Athens, Greece: Results from the Aristotle ProgrammeVana Sypsa, National and Kapodestrian University of Athens, Greece

2.55pm - 3.00pm

Multi-Disciplinary Managed Care Networks-Lifesaving Interventions for Hepatitis C PatientsJohn Dillon, University of Dundee, United Kingdom

3.00pm - 3.30pm


3.30pm - 3.45pm

Poster Highlights Room: Scandinavia Ballroom Chair: Jason Grebely, The Kirby Institute, University of New South Wales, Australia

3.45pm - 5.00pm

Session E: Limiting the HCV Epidemic

Room: Scandinavia BallroomChairs: Kimberly Page, University of New Mexico Health Sciences Center, United States of America and Berne Stålenkrantz, The Swedish Drug Users Union, Sweden

3.45pm - 4.05pm

State-of-the-Art Lecture: HCV Treatment as Prevention Matthew Hickman, University of Bristol, United Kingdom

4.05pm - 4.25pm

HCV Vaccine Development: Where Do We Stand? Andrea Cox, John Hopkins University, United States of America

4.25pm - 4.45pm

The Ebola Vaccine Experience: Cluster Randomisation and Implications for HCV Trial Design John-Arne Røttingen, Norwegian Institute of Public Health, Norway

4.45pm - 5.00pm

Liver Or Die: A Peer Training Manual Berne Stålenkrantz, The Swedish Drug Users Union, Sweden

5.00pm - 6.30pm

Welcome Reception & Poster Viewing Session in Foyer

8

PROGRAMME: Thursday 8 September

TREATMENT AND CARE

9.00am - 10.30am

Session F: HCV Treatment Among PWID

Room: Scandinavia BallroomChairs: Julie Bruneau, Université de Montréal, Canada and Margaret Maher, EuroNPUD, United Kingdom

9.00am - 9.20am

State-of-the-Art Lecture: Treatment of HCV Infection in 2016 Graham Foster, University of London, United Kingdom

9.20am - 9.40am

HCV Treatment Trials among PWID Gregory Dore, The Kirby Institute, University of New South Wales, Australia

9.40am - 9.55am

Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine Sergii Filippovych, International Charitable Foundation “Alliance for Public Health”, Ukraine

9.55am - 10.10am

C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons Who Inject Drugs Receiving Opioid Agonist TherapyOlav Dalgard, Akershus University Hospital, Norway

10.10am - 10.25am

“I got my life back!” - Patients’ experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients. Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital, Denmark

10.25am - 11.00am


11.00am - 12.00pm

Session G: Living with HCV Infection

Room: Scandinavia BallroomChairs: Philip Bruggmann, Arud Zentren Für Suchtmedizin, Switzerland and Jude Byrne, Australian Injecting & Illicit Drug Users League, Australia

11.00am - 11.10am

Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue? Olav Dalgard, Akershus University Hospital, Norway

11.10am - 11.20am

The Patient Perspective Andi Hüttenmoser, Switzerland

11.20am - 11.30am

“But a spoon is not equipment”: Risk Behaviour and Knowledge Seeking among HCV-infected PWID Alexandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences

11.30am - 12.00pm

Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use? Moderator: Graham Foster, University of London, United Kingdom Anne Øvrehus, University of Southern Denmark, DenmarkMartin Kåberg, Karolinska Institutet, SwedenSharon Hutchinson, Glasgow Caledonian University, United KingdomPeer Brehm Christensen, University of Southern Denmark, Denmark

12.00pm - 1.45pm

Lunch in Restaurant

12.15pm - 1.15pm

Industry Sponsored Symposium: Making HCV Elimination a Reality for PWID Room: Stockholm/Oslo


TREATMENT AND CARE

9.00am - 10.30am

Session F: HCV Treatment Among PWID

Room: Scandinavia BallroomChairs: Julie Bruneau, Université de Montréal, Canada and Margaret Maher, EuroNPUD, United Kingdom

9.00am - 9.20am

State-of-the-Art Lecture: Treatment of HCV Infection in 2016 Graham Foster, University of London, United Kingdom

9.20am - 9.40am

HCV Treatment Trials among PWID Gregory Dore, The Kirby Institute, University of New South Wales, Australia

9.40am - 9.55am

Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine Sergii Filippovych, International Charitable Foundation “Alliance for Public Health”, Ukraine

9.55am - 10.10am

C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons Who Inject Drugs Receiving Opioid Agonist TherapyOlav Dalgard, Akershus University Hospital, Norway

10.10am - 10.25am

“I got my life back!” - Patients’ experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients. Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital, Denmark

10.25am - 11.00am


11.00am - 12.00pm

Session G: Living with HCV Infection

Room: Scandinavia BallroomChairs: Philip Bruggmann, Arud Zentren Für Suchtmedizin, Switzerland and Jude Byrne, Australian Injecting & Illicit Drug Users League, Australia

11.00am - 11.10am

Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue? Olav Dalgard, Akershus University Hospital, Norway

11.10am - 11.20am

The Patient Perspective Andi Hüttenmoser, Switzerland

11.20am - 11.30am

“But a spoon is not equipment”: Risk Behaviour and Knowledge Seeking among HCV-infected PWID Alexandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences

11.30am - 12.00pm

Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use? Moderator: Graham Foster, University of London, United Kingdom Anne Øvrehus, University of Southern Denmark, DenmarkMartin Kåberg, Karolinska Institutet, SwedenSharon Hutchinson, Glasgow Caledonian University, United KingdomPeer Brehm Christensen, University of Southern Denmark, Denmark

12.00pm - 1.45pm

Lunch in Restaurant

12.15pm - 1.15pm

Industry Sponsored Symposium: Making HCV Elimination a Reality for PWID Room: Stockholm/Oslo

TREATMENT AND CARE

1.45pm - 3.00pm

Session H: Oral Abstracts Clinical

1.45pm - 3.00pm

Session I: Oral Abstracts Social Sciences and Community

Room: KøbenhavnChairs: Brian Conway, Vancouver ID Centre, Canada and Georgios Zarkotos, Greek Drug Users Union, Greece

Room: Stockholm/Oslo Chairs: Carla Treloar, Centre for Social Research in Health, Univeristy of New South Wales, Australia

1.45pm - 2.00pm

Outreach Screening and Treatment for Hepatitis C in a Drug Treatment Unit – An Exploratory Assessment of Feasibility and Cost EffectivenessAshley Brown, St Mary’s Hospital, United Kingdom

1.45pm - 2.00pm

Relationships and Injecting Dyads: Identifying Key Interpersonal Factors Underlying Injecting Behaviors and Hepatitis C Virus (HCV) Transmission among Injecting PartnershipsMeghan Morris, University of California, San Francisco, United States of America

2.00pm - 2.15pm

High Rates of Sustained Virological Response in People Who Inject Drugs Treated with All-Oral Direct Acting Antiviral RegimensAlain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center, United States of America

2.00pm - 2.15pm

Becoming a Buddy: Accordance and Incompatibility in the Hepatitis C Peer Support RoleMagdalena Harris, London School of Hygiene and Tropical Medicine, United States of America

2.15pm - 2.30pm

Real World Outcomes of Direct Acting Antiviral (DAA) Therapy for Hepatitis C (HCV) Amongst Persons Who Inject Drugs Treated in an Inner-city Hepatitis C treatment Program, Vancouver, CanadaMark Hull, BC Centre for Excellence in HIV/AIDS, Canada

2.15pm - 2.30pm

Qualitative Evaluation of the Decisions and Experiences of People who Inject Drugs who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife StudyAlison Marshall, The Kirby Institute University of New South Wales, Australia

2.30pm - 2.45pm

Comparison of Rates of Recurrent HCV Viremia in High-Risk Patients Receiving All-Oral and Interferon-Based RegimensTyler Raycraft, Vancouver ID Research and Care Centre Society, Canada

2.30pm - 2.45pm

Qualitative Insights into the Lived Experience of Interferon-Free TreatmentsDavid Whiteley, Edinburgh Napier University, United Kingdom

2.45pm - 2.50pm

Treatment Evaluation and Uptake among Persons with Chronic Hepatitis C on Opium Substitution Therapy. Is Treatment as Prevention Realistic?Anne Øvrehus, Odense University Hospital, Denmark

2.45pm - 2.50pm

The Australian Response and Uptake of the New Subsidised Hepatitis C Direct Acting Anti-Virals among the Community of People Who Inject DrugsJude Byrne, The Australian Injecting and Illicit Drug users League, Australia

10

TREATMENT AND CARE

2.50pm - 2.55pm

Optimal Adherence during HCV Treatment amongst Active Drug Users at a Community Based Program in Toronto, CanadaKate Mason, South Riverdale Community Health Centre, Canada

2.50pm - 2.55pm

Blood Borne Virus Risk Behaviours among People Who Inject Drugs in the UK: A Qualitative ExplorationDavina Swan, King’s College London, United Kingdom

2.55pm - 3.00pm

Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot StudyBrianna Norton, Division of Internal Medicine, Montefiore Medical Center, United States of America

2.55pm - 3.00pm

Utilising Social Capital to Promote HCV Treatment in PrisonLise Lafferty, The Kirby Institute, University of New South Wales, Australia

3.00pm - 3.30pm


3.30pm - 5.00pm

Session J: Assessment and Management of HCV Infection

Room: Scandinavia BallroomChairs: Jason Grebely, Kirby Institute, University of New South Wales, Australia and Kanta Rajkumar, CONE, India

3.30pm - 3.50pm

Simplified HCV Diagnostics Teri Roberts, MSF Access Campaign, Switzerland

3.50pm - 4.00pm

It’s Your Liver: Peer to Peer HCV Testing and Education Bent Arild Stornes, ProLAR, Norway

4.00pm - 4.20pm

Liver Disease Assessment among PWID: The Role of Transient Elastography Peer Brehm Christensen, University of Southern Denmark, Denmark

4.20pm - 4.40pm

HCV Reinfection Following Successful Treatment: Clinical and Public Health Implications Håvard Midgard, Akershus University Hospital, Norway

4.40pm - 5.00pm

Understanding Liver Cirrhosis and its Complications John Willy Haukeland, Oslo University Hospital, Norway

5.00pm - 6.00pm

INHSU General Assembly Members Meeting

7.00pm - 11.00pm

Conference Dinner at Posthallen

PROGRAMME: Thursday 8 September


PROGRAMME: Friday 9 September

ACCESS AND IMPLEMENTATION

Session K: Parallel Workshops

8.30am - 10.00am

Workshop #1: Getting Involved: Peer SupportLocation: HelsingforsChair: Berne Stålenkrantz, The Swedish Drug Users Union, Sweden

Workshop #2: HCV Prevention: What Works and What Doesn’t?Location: KøbenhavnChair: Holly Hagan, New York University, United States of America and Eberhard Schatz, Correlation Network, Netherlands

Workshop #3: HCV Testing and Care in PrisonsLocation: StockholmChair: Andrew Lloyd, University of New South Wales, Australia and Pernille Sauer, Aarhus University Hospital, Denmark

Workshop #4: Liver Disease Assessment among PWID: Hands OnLocation: OsloChairs: Peer Brehm Christensen, University of Southern Denmark, Denmark; Håvard Midgard, Akershus University Hospital, Norway

Workshop #5: The Low Threshold HCV ClinicLocation: SkagerakChair: John F Dillon, University of Dundee, United Kingdom and Leon Wylie, Hepatitis Scotland, United Kingdom

Workshop #6: HCV Epidemiology: Populations, Data Sources and Missing DataLocation: EidsvollChair: Matthew Hickman, University of Bristol, United Kingdom, Greg Dore, The Kirby Institute, University of New South Wales, Australia and Julie Bruneau, Université de Montréal, Canada

10.00am - 10.45am


10.45am - 12.00pm

Session L: Novel Models of HCV Care

Room: Scandinavia BallroomChairs: Greg Dore, The Kirby Institute, University of New South Wales, Australia and Mary Harrod, New South Wales Users & AIDS Association, Australia

10.45am - 11.05am

HCV Treatment in the Prison Setting Andrew Lloyd, University of New South Wales, Australia

11.05am - 11.25am

Pharmacy Based HCV Treatment John F Dillon, University of Dundee, United Kingdom

11.25am - 11.40am

Decentralised HCV Shared Care: The SACC Project Lars Peters, Rigshospitalet, Denmark

11.40am - 12.00pm

New Technologies for Addressing Treatment Barriers and Treatment AdherenceJeffrey J Weiss, Mount Sinai Hospital, United States of America

12.00pm - 1.45pm

Lunch in Restaurant

12.15pm - 1.15pm

Industry Sponsored Symposium: TREAT TO CURE. TREAT TO PREVENT:Management of Substance Users with HCV Infection Room: Scandinavia Ballroom

12

ACCESS AND IMPLEMENTATION

1.45pm - 2.45pm

Session M: Drug Policy

Room: Scandinavia BallroomChairs: Margaret Hellard, Burnet Institute, Australia and Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia

1.45pm - 2.05pm

War on Drugs or War on Disease? Ethan Nadelmann, Drug Policy Alliance, United States of America

2.05pm - 2.25pm

Report from United Nations General Assembly Special Session on the World Drug Problem 2016 Daniel Wolfe, Open Society Foundations, United States of America

2.25pm - 2.30pm

HA-REACT: The European Joint Action on HIV and Coinfection Prevention and Harm Reduction - What’s in it for Hepatitis? Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark

2.30pm - 2.50pm

Can information and communication technologies (ICTs) increase treatment opportunities for people who are homeless and people who inject drugs? Jo Neale, King’s College London, United Kingdom

2.50pm - 3.00pm

The INHSU Video Project Nikki Cavenagh, The Digital Clinic, Australia

3.00pm - 3.15pm


3.15pm - 4.00pm

Session N: HCV Care in Resource-Limited Countries

Room: Scandinavia BallroomChairs: Jeff Lazarus, Rigshospitalet, University of Copenhagen, Denmark and Janko Belin, Društvo AREAL, Slovenia

3.15pm - 3.35pm

The Georgia HCV Elimination Program Maia Butsashvili, Health Research Union, Georgia

3.35pm - 3.55pm

Russia: Hepatitis C Treatment Gap and Ways Forward Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia

3.55pm - 4.15pm

Access to DAAs from an Asian Perspective Giten Khwairakpam, TREAT Asia, Thailand

4.15pm - 4.25pm

HCV Infection among PWID: Research Priorities for Optimizing Prevention, Management and Treatment in the Era of DAAs Jason Grebely, The Kirby Institute, University of New South Wales, Australia

4.25pm - 4.30pm

Conference Closing in Scandinavia Ballroom

PROGRAMME: Friday 9 September


POSTER LISTINGPosters will be displayed in Helsingfors Room

# TITLE OF ABSTRACT PRESENTER

01Addressing HIV/HCV Co-Infection among Injecting Drug Users in Jakarta, Indonesia using Peer Driven Intervention

EDO AGUSTIAN

02Circumstances around First Drug Injection and Prevalence of HIV, Hepatitis B (HBV) and Hepatitis C (HCV) Among Participants of a Needle Exchange Program (NEP)

MARIANNE ALANKO BLOMÉ

03Cause-Specific Mortality among People with a Hepatitis C Notification: A Population-Based Linkage Study, 1993- 2012

MARYAM ALAVI

04Reduced HCV Recurrent Viremia in PWID with Treatment Induced Virologic Clearance through a Comprehensive Multidisciplinary Treatment Model

ARSHIA ALIMOHAMMADI

05Hepatitis B Virus (HBV) Serological Status among People Who Enter the Opioid Substitution Programme in Greece

OLGA ANAGNOSTOU

06Incidence and Predictors of Hepatitis C Treatment Initiation among People who Inject Drugs: Longitudinal Data from a Greek Tertiary Center, 2009-2015.

OLGA ANAGNOSTOU

07Low-Threshold Hepatitis C Treatment for People Who Inject Drug – How to Ensure Compliance and Treatment Success

ØYSTEIN BACKE / KRISTIN VENNESLAND

08Modelling Hepatitis C Virus Transmission in a High-Risk Incarcerated Population

NEIL BRETANA

09HCV Treatment Initiation among HCV Infected PWID in Capica, A Retrospective Study in Twelve Canadian Clinical Settings

JULIE BRUNEAU

10Heroin Assisted Treatment Setting: Feasibility and Efficacy of Hepatitis C DAA Treatment

NATHALIE BRUNNER

11Hepatitis C Testing in the General Practice Setting for Australians Who Inject Drugs

KERRYN BUTLER

12 Hepatitis C Virus RNA Quantification on Dry Capillary Blood Spot ERIKA CASTRO

13 DAA 2nd Generation Treatment Outcome in Substance Users ERIKA CASTRO

14Attitudes towards Hepatitis C and Treatment Willingness among People Who Inject Drugs: A Follow- Up Interview Study

DISA DAHLMAN

15Stage of Liver Disease in Hepatitis C Patients at a Low- Threshold Hepatitis C Clinic in Oslo

OLAV DALGARD

16High Hepatitis C Virus Reinfection Rate after Achieving Sustained Virological Response (Svr) among People who Inject Drugs Actively: Tactic Cohort

LUCIE DESHAIES

14


17Trends In Hepatocellular Carcinoma Among People Receiving Opioid Substitution Therapy With an HCV Notification In New South Wales, Australia Between 2000 and 2014

GREG DORE

18Baseline Characteristics and Recruitment in a Randomised Trial of Community Vs Hospital Direct Acting Antiviral Treatment for Hepatitis C

JOSEPH DOYLE

19Eliminating Hepatitis C Transmission by Enhancing Care and Treatment among HIV Co-Infected Individuals: The Co-EC Study

JOSEPH DOYLE

20Experiences of alcohol use and hepatitis c among people who inject drugs: implications for treatment services.

JANE EVELY

21 HCV Capacity Building Trainings for Harm Reduction and Peer Workers JASON FARRELL

22High Rates of Sustained Virological Response in People Who Inject Drugs Treated With Sofosbuvir-Based Regimens in Ukraine

SERGII FILIPPOVYCH

23Intermittent Injecting Drug Use and HCV Incidence in an Observational Cohort Study of People Who Inject Drugs in Montréal, Canada

EMMANUEL FORTIER

24Scaling Up HCV Treatment, Syringe Services and Medicated-Assisted Treatment for Achieving Rapid HCV Elimination in Rural America – Model Projections For Indiana

HANNAH FRASER

25Real World Experience in HCV Awareness, Testing, Care and Knowledge Transfer in La Ronge, Saskatchewan

LESLEY GALLAGHER

26Past Incarceration Experience and the Risk of Hepatitis C Infection among People Who Inject Drugs: Results from a Sero-Behavioral Survey among Current Injectors in Germany

MARTYNA GASSOWSKI

27Efficacy of Sofosbuvir/Ledipasvir With and Without Ribavirin in Patients with Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

JASON GREBELY

28Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

JASON GREBELY

29 Efficacy of All-Oral HCV Therapy in People who Inject Drugs SYUNE HAKOBYAN

30Portable Pop-Up Clinics: Characteristics of Engagement in Care, an Observational Prospective Cohort Study

SYUNE HAKOBYAN

31Analysis of Adherence to All-Oral HCV Therapy in a Cohort of People Who Inject Drugs (PWID)

SYUNE HAKOBYAN

32

Direct observed therapy of Chronic Hepatitis C with Interferon-Free All-Oral regimens at a Low-Threshold Drug Treatment facility – A new concept for treatment of patients with Borderline Compliance receiving Opioid Substitution Therapy

HANS HALTMAYER

POSTER LISTING



33Peer Support for People Living with Hepatitis C in Drug and Alcohol Settings Increases Hep C Assessment and Knowledge

MARY HARROD

34Ethical Research and Engagement with People Who Use Drugs: Frameworks and Implementation

MARY HARROD

35Geographic Determinants of Hepatitis C Screening in a Mixed Urban/Rural Epidemic

KARLI HOCHSTATTER

36Hepatitis C Testing and Undiagnosed Infections among People Injecting Image and Performance Enhancing Drugs in England & Wales: 2012-15

VIVIAN HOPE

37Factors Associated with Entry into Healthcare Pathways for Hepatitis C among People who Inject Psychoactive Drugs in the United Kingdom (UK)

VIVIAN HOPE

38Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia

JENNY IVERSEN

39Infcare Needle Syringe Program (Infcare NSP), A Database for following and Reducing Injection Risk Behavior Over Time in PWID in Stockholm

MARTIN KÅBERG

40Pre-Testing Knowledge of Hepatitis C Status among 1504 Consecutive Participants at the Stockholm Needle Exchange

MARTIN KÅBERG

41 Does Chronic Hepatitis C Cause Fatigue? KNUT BOE KIELLAND

42 Injecting Drug Use Among Inmate in Norwegian Prisons KNUT BOE KIELLAND

43Aggressive Treatment of Hepatitis C in People Who Inject Drugs in Norway: An Integral Step to Eradicate the Infection in this Population

KNUT BOE KIELLAND

44The Hep-NORDIC project: viral hepatitis c management policies for people who inject drugs in the five Nordic countries

JEFFREY LAZARUS

45Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Pakistan

AARON LIM

46Impact of HCV Advocacy and Demonstration Treatment Programs Specifically Targeted at PWIDS on National Hepatitis Policy

LUDMILA MAISTAT

47A Qualitative Study of the Perceptions of Interferon- Free Therapy for Hepatitis C Virus Infection among People Who Inject Drugs: The Liver life Study

ALISON MARSHALL

48Substantial Decline of Hepatitis C Virus Prevalence among PWID in Flanders, Belgium: The Result of a Comprehensive Approach

CATHARINA MATHEÏ

49 Earth Study (Phase 1): Expanding Access to Rapid Treatment for Hep C DEE MENEZES

50Reinfection of Hepatitis C among People Who Inject Drugs in Norway: Opportunity for Intervention-A Modelling Study

HAVARD MIDGARD

16

POSTER LISTING


51Improved Access to HCV Treatment for Substance Users: The Impact of On-Site Transient Elastography in an Inner City Community Health Centre

ROZALYN MILNE

52Prospective Data on People Who Use Drugs in Switzerland: The SAMMSU Cohort

ALBERTO MORIGGIA

53High Prevalence of Liver Fibrosis among People Attending Addiction Clinics and Rehabilitation Facilities in Southern Switzerland: Results of Two Different Screening Programs for Liver Disease

ALBERTO MORIGGIA

54Development and Validation of a Novel Measurement Scale for Interpersonal Factors Underlying Injection Drug Using Behaviors

MEGHAN MORRIS

55Dried Blood Spot, Valid Screening Method for Viral Hepatitis and HIV in Real-Life

BELINDA KLEMMENSEN MÖSSNER

56Low Levels of HCV Awareness and Risk Among Groups Most at Risk in Vietnam

HUONG NGO

57Concordance between Self-Reported and Measured HIV and Hepatitis C Virus Infection Status among People Who Inject Drugs in Germany

STINE NIELSEN

58Are There Missed Opportunities for Vaccinating Against Hepatitis B among People Who Inject Drugs (PWID) In The United Kingdom (UK)?

JACQUELYN NJOROGE

59Dot-C: A Pilot Trial of Directly Observed Anti HCV Therapy in a Population Receiving Opiate Substitution Therapy (OST) from a Pharmacy - Uptake of Testing Results

ANDREW RADLEY

60Adherence to Hepatitis C Treatment Regimen among People Who Inject Drugs in Norway: Implications for Treatment Strategies

DEVIN RAZAVI-SHEARER

61Compass Project, Inside and Outside Link for Prisoners and PWID with Hepatitis C in France

ANDRE JEAN REMY

62Global Genotype Distribution of Hepatitis C Viral Infection among People who Inject Drugs

GEERT ROBAEYS

63Hepatitis C Treatment on PWUD in the DAA’S Era: High Rate of Virological Response in the Real Life

ANTONELLA ROBATTO

64Trends of Hepatitis C Virus Epidemic in Australia and North America in 20th Century: Back Projections from Molecular Epidemiology

CHATURAKA RODRIGO

65Drug Market Variations and Drug Use Practices among People Who Inject Drugs in the Province of Québec, Canada

ÉLISE ROY

66Hepatitis C and Risk Behavior among Persons Who Inject Drugs in Norway

RIKARD RYKKVIN



67The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk Behaviours among People Who Inject Drugs: A Systematic Review and Meta-Analysis

DAVINA SWAN

68Training Drug Users in Overdose Reversal with Intranasal Naloxone – A New Approach to Address Opioid Overdoses and other General Health Problems

HENRIK THIESEN

69The Effects of Alcohol on Spontaneous Clearance of Acute Hepatitis C Virus Infection in Females versus Males Who Inject Drugs

JUDITH TSUI

70Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Infection in a Low Threshold Setting

KJERSTI ULSTEIN

71Prevalence and Determinants of Liver Disease among People who use Drugs in Amsterdam, The Netherlands

DANIELA VAN SANTEN

72From the Users’ Perspective – An Interview Study with People who Inject Drugs on the Usefulness of Participating in a Needle Syringe Program

MALIN VÄRMÅ FALK

73Impact of Current and Scaled Up Levels of Needle and Syringe Programmes and Opiate Substitution Therapy in Three UK Settings

ZOE WARD

74C-Buddies: Missing Piece of the Puzzle in a Comprehensive “Not Under One Roof“. Approach for Hepatitis C Management Among People Who Use Drugs

TESSA WINDELINCKX

75Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic

VICCI GOODWIN

a Estimates are based on peginterferon + ribavirin treatment era and some date back to 2008.1,2

1. Grebely J, Dore GJ. Antiviral Res 2014;104:62–72. 2. European Centre for Disease Prevention and Control, 2015. Hepatitis C surveillance in Europe – 2013. Stockholm: ECDC. Available from http://ecdc.europa.eu/en/publications/Publications/hepatitis-c-surveillance-in-europe-2013.pdf. Accessed July 2016. 3. Perlman DC et al. Int J Drug Policy 2015;26:1056–1063.

© 2016 Gilead Sciences Europe Limited HCV/IHQ/16-07//1999 Date of preparation: July 2016

67% OF PEOPLE WHO INJECT DRUGS

HAVE HEPATITIS C, GLOBALLY1

10 MILLIONPEOPLE WHO INJECT

DRUGS IN THE WORLD HAVE HEPATITIS C1

~80% OF NEW HEPATITIS C INFECTIONS RESULT

FROM INJECTION DRUG USE2

~90% OF HEPATITIS C

PATIENTS WHO INJECT DRUGS FAIL TO INITIATE

HEPATITIS C TREATMENT1,3,a

SCREEN DIAGNOSE REFERYou are the first step towards cure

20

VENUE FLOOR PLAN

SCANDINAVIA BALLROOM

Hels

ing

fors

Kø

ben

havn

Sto

ckh

olm

Osl

o

Pos

ters

Ple

nary

Roo

m /

Ses

sion

sSp

eake

r Pre

par

atio

n Roo

m

Exh

ibitio

n

Lunc

h

Holberg Restaurant


LOCATION MAP

SENTRUM

OSLO

Opera House

Slottsparken

Barcode Project

Posthallen

MSD (Norge) AS, Pb. 458 Brakerøya, 3002 Drammen, tlf. 32 20 73 00, faks 32 20 73 10Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. INFC-1175295-0014 08/16

AN UNWAVERING COMMITMENT TO THE TASK AT HAND

Where a 25-year legacy of innovation in chronic HEPATITIS C treatment1–3 meets

HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES4 According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: It claims the lives of approximately 500,000 people per year.5 However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.

References: 1. PEG-intron and ribavirin combination product approval letter. FDA: August 7, 2001. 2. Victrelis® (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union for treatment of chronic hepatitis C [news release EU version]. Whitehouse Station, NJ: MSD; July 18, 2011. 3. Intron A Registration Life Cycle Status as of January 21, 2011 [FDA]. 4. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed August 4, 2015. 5. World Health Organization. WHO Key Facts. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 11, 2015.


SOCIAL FUNCTIONS

If you have not confirmed your attendance at any of these events please advise the secretariat at registration urgently for catering purposes.

WELCOME RECEPTIONDate: Wednesday 7 September 2016 Time: 5.00pm - 6.30pm Venue: Foyer, Radisson Blu Scandinavia Hotel

Inclusive in all registrations Guest ticket: ¤50.00

Dress: Smart Casual

CONFERENCE DINNERDate: Thursday 8 September 2016 Time: 7pm - 11pm Venue: Posthallen

Venue details:

� Address: Prinsens gate 8, 0152 Oslo

� Phone: 22:42 82 00

� Fax: 22:42 82 01

� Email: [email protected]

Delegate ticket: ¤100.00 Guest ticket: ¤110.00

Dress: Smart Casual

MSD (Norge) AS, Pb. 458 Brakerøya, 3002 Drammen, tlf. 32 20 73 00, faks 32 20 73 10Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. INFC-1175295-0014 08/16

AN UNWAVERING COMMITMENT TO THE TASK AT HAND

Where a 25-year legacy of innovation in chronic HEPATITIS C treatment1–3 meets

HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES4 According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: It claims the lives of approximately 500,000 people per year.5 However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.

References: 1. PEG-intron and ribavirin combination product approval letter. FDA: August 7, 2001. 2. Victrelis® (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union for treatment of chronic hepatitis C [news release EU version]. Whitehouse Station, NJ: MSD; July 18, 2011. 3. Intron A Registration Life Cycle Status as of January 21, 2011 [FDA]. 4. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed August 4, 2015. 5. World Health Organization. WHO Key Facts. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 11, 2015.

24

INDUSTRY SPONSORED SYMPOSIA

A PRACTICAL APPROACH TO TREATING HCV IN PWIDWhen: Wednesday 7 September, 12.15pm - 1.15pm Where: Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration

Symposium Synopsis: MSD is pleased to present a symposium entitled “A Practical Approach to Treating HCV in PWID.” An internationally renowned faculty chaired by Olav Dalgard will present emerging data on the treatment HCV in PWID. The first lecture by Mojca Maticic will focus on treatment considerations of the PWID including the quality of life of PWIDs, continued drug use, reinfection and barriers to treatment. The second lecture by Ashley Brown will review underlying comorbidities in PWID including an discussion on common co-morbidities such as co-infection, psychiatric conditions and extra-hepatic manifestations in younger vs older PWID, gender differences in co-morbidities and how to manage co-morbidities to ensure a successful treatment.

MAKING HCV ELIMINATION A REALITY FOR PWIDWhen: Thursday 8 September, 12.15pm - 1.15pm Where: Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration

Symposium Synopsis: With HCV cure rates of more than 90%, the direct-acting antiviral agents afford the opportunity to eliminate HCV infection from groups of affected patients. In medium-to-high income countries people who inject drugs are disproportionately affected by HCV. Low HCV treatment uptake among people who inject drugs indicate that these patients come up against many challenges in accessing HCV treatment and care. In this educational symposium the faculty will be focusing on what is being done from a global policy perspective and what needs to be done at a country level to make HCV elimination a reality.


TREAT TO CURE. TREAT TO PREVENT. Management of Substance Users with HCV Infection

When: Friday 9 September, 12.15pm - 1.15pm Where: Scandinavia Ballroom, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration

Symposium Synopsis: The past decade has seen unprecedented advances in hepatitis C treatment with new highly effective all-oral interferon-free direct-acting antiviral therapies. Drug users have traditionally been a challenging patient population to treat and can be at risk of reinfection following successful treatment.

This cutting-edge AbbVie-sponsored symposium will cover topics ranging from current treatment options and access to care, to treatment to prevent the spread of hepatitis C in people who use drugs.

We would be delighted to invite you to this symposium with some of the world’s leading experts in the field of viral hepatitis. With the opportunity to pose questions to the panel, this debate-style symposium promises to be an interactive and educational meeting that will address a wide range of issues facing physicians today.

28

EXHIBITION BOOTH LISTING

BOOTH 1Echosens is a pioneer in non-invasive diagnosis solutions in hepatology.

FibroScan®, based on proprietary Vibration Control Transient Elastography ™, is the only worldwide clinically validated medical device using elastography with more than 900 peer-reviewed publications.

FibroMeter® is a range of scores combining several blood biomarkers to measure the degree of fibrosis in the liver.

FibroView™ offers a broad range of smart connectivity solutions linking FibroScan® to the HIS (Hospital Information Systems).

BOOTH 2

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.

BOOTH 3/4

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.

BOOTH 5/6

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. We demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.


3/4

7/85/6

21

9

Reception

Hotel Lobby >

BOOTH 7/8

AbbVie is a global biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. Its mission is to develop and market therapies that address some of the world’s most complex and serious diseases. Together with its subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people and markets medicines in more than 170 countries.

BOOTH 9

The International Network on Hepatitis Care in Substance Users (INHSU) is an international organization dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care with people who use drugs.

At Cepheid we are focused on providing fast and actionable results that improve patient outcomes and reduce complications in the most vulnerable populations. Please visit the Cepheid booth to experience how same day, on-demand and ultrasensitive molecular results can impact the HCV epidemic now.

Come visit us at the Cepheid Booth #2

Revolutionizing HCV Management in PWID*

* People Who Inject Drugs

CE-IVD. Not available in all countries.


NOTES

At Cepheid we are focused on providing fast and actionable results that improve patient outcomes and reduce complications in the most vulnerable populations. Please visit the Cepheid booth to experience how same day, on-demand and ultrasensitive molecular results can impact the HCV epidemic now.

Come visit us at the Cepheid Booth #2

Revolutionizing HCV Management in PWID*

* People Who Inject Drugs

CE-IVD. Not available in all countries.

32

NOTES


INHSU CONFERENCE 2016

THANK YOU TO OUR SPONSORS & SUPPORTERS

Platinum Sponsors

Bronze Sponsor

INHSU 2016

inhsu 2016 conference handbook

Documents